In situ treatment with a TLR9 agonist virus-like particle to promote immune responses against oral epithelial dysplasia progression.
Saved in:
| Title: | In situ treatment with a TLR9 agonist virus-like particle to promote immune responses against oral epithelial dysplasia progression. |
|---|---|
| Authors: | Xu Y; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA., Mcmillan A; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Department of Otolaryngology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA., Gupta N; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA., Lemke-Miltner CD; Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA, USA.; Department of Internal Medicine, The University of Iowa, Iowa City, IA, USA., Rataan AO; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan., Areecheewakul S; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand., Bhat DS; Department of Internal Medicine, The University of Iowa, Iowa City, IA, USA., Lanzel EA; Department of Oral Pathology, Radiology and Medicine, College of Dentistry, University of Iowa, Iowa City, IA, USA., Geary SM; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA., Simons AL; Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA, USA.; Department of Oral Pathology, Radiology and Medicine, College of Dentistry, University of Iowa, Iowa City, IA, USA.; Department of Pathology, University of Iowa, Iowa City, IA, USA.; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.; Department of Radiation Oncology, Carver College of Medicine, Iowa City, United States., Weiner GJ; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA, USA.; Department of Internal Medicine, The University of Iowa, Iowa City, IA, USA., Salem AK; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA. aliasger-salem@uiowa.edu.; Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA, USA. aliasger-salem@uiowa.edu. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 May 03; Vol. 74 (6), pp. 189. Date of Electronic Publication: 2025 May 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-025-04023-1 |
